Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2025
0mins
Should l Buy ELAB?
Source: Benzinga
Circle Internet Group IPO Success: Circle Internet Group's shares surged over 29% following its IPO, opening at $69 and reaching a pre-market trading price of $126.99, reflecting strong market interest in the USDC stablecoin issuer.
Pre-Market Trading Highlights: Several stocks experienced significant movements in pre-market trading, with Klotho Neurosciences rising 123.5% due to positive gene therapy news, while Sunnova Energy saw a decline of 27% after disappointing performance results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAB
About ELAB
PMGC Holdings Inc. is a diversified holding company. Its operating companies include Northstrive Biosciences Inc., PMGC Capital LLC, Pacific Sun Packaging, Inc. AGA Precision Systems LLC, NorthStrive Defense Tech LLC and A&B Aerospace, Inc. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on development and acquisition of aesthetic medicines and therapeutic products. PMGC Capital LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Pacific Sun Packaging, Inc. is a specialty packaging provider focused on high-precision, component-level packaging solutions for the electronics and information technology hardware industries. AGA Precision Systems LLC is a specialized computer numerical control machine shop. NorthStrive Defense Tech LLC is focused on identifying, acquiring and commercializing advanced defense technologies (emphasis on drone and autonomous systems).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GB Capital Advises PMGC on A&B Aerospace Acquisition
- Acquisition Overview: PMGC Holdings Inc. has completed the acquisition of A&B Aerospace, marking its fifth acquisition in the past 12 months and further advancing its consolidation strategy in the U.S. precision manufacturing sector, which is expected to enhance its market competitiveness.
- Stable Customer Base: A&B Aerospace has established contracts with long-standing Tier 1 customers such as Boeing, Honeywell, and Moog, ensuring ongoing demand in the aerospace and defense sectors, thereby providing PMGC with a stable revenue stream.
- Significant Technical Advantages: A&B Aerospace specializes in high-tolerance machining and complex component manufacturing, operating over 20 modern CNC machines with full 5-axis capabilities, maintaining strict tolerances of ±0.0001 inches, which enhances PMGC's technical barriers to entry.
- Comprehensive Financial Support: GB Capital provided extensive financial due diligence and post-closing integration support throughout the transaction lifecycle, including standardizing financial reporting and internal controls, ensuring PMGC's compliance and operational efficiency post-acquisition.
See More
Elevai Labs Reports Significant Q1 Revenue Growth
- Revenue Growth: Elevai Labs reported Q1 revenue of $0.68 million, indicating strong market performance that is expected to drive future business expansion and investment opportunities.
- Asset Increase: As of March 31, 2026, total assets rose to approximately $26.0 million, up 102% from $12.87 million at year-end 2025, demonstrating the company's success in capital management and resource allocation.
- Shareholder Equity Growth: Shareholders' equity increased to approximately $12.6 million, a 61% rise from $7.84 million at year-end 2025, reflecting enhanced profitability and increased shareholder value.
- Improved Cash Flow: Cash and cash equivalents ended the quarter at approximately $14.4 million, significantly up from $5.4 million at year-end 2025, marking the largest cash balance in the company's history and providing ample funding for future investments.
See More
PMGC Holdings Reports Q1 2026 Financial Results with Significant Growth
- Significant Asset Growth: As of March 31, 2026, PMGC Holdings reported total assets of approximately $26 million, a 102% increase from $12.87 million at the end of 2025, reflecting strong performance in financing and M&A activities that enhance financial stability.
- Shareholder Equity Increase: Shareholder equity rose to approximately $12.6 million, up 61% from $7.84 million at year-end 2025, indicating improved profitability and providing a stronger capital base for future investments and expansions.
- Revenue Surge: Q1 2026 revenue reached approximately $682,000, a significant increase from zero in the same period of 2025, and surpassing the entire FY2025 revenue of $590,000, demonstrating rapid revenue growth post-acquisition.
- Strategic Investment Expansion: The company formed NorthStrive Defense Tech LLC in April 2026 to focus on acquiring and commercializing advanced defense technologies, while also entering into a $40 million equity purchase agreement with an investor, ensuring future capital flexibility to support M&A activities.
See More
PMGC Holdings Acquires A&B Aerospace for $4.5M
- Acquisition Overview: PMGC Holdings has acquired A&B Aerospace for $4.5 million in cash, with $4.275 million paid at closing and a $225,000 indemnification holdback, demonstrating the company's commitment to expanding in the aerospace manufacturing sector.
- Strategic Acquisition Progress: This deal marks PMGC's fifth acquisition in the past twelve months, further advancing its roll-up strategy focused on assembling a U.S. precision manufacturing platform of AS9100D-certified CNC machining businesses serving aerospace, defense, and industrial markets.
- Financial Performance Highlights: For the trailing twelve-month period ending February 28, 2026, A&B Aerospace recorded approximately $5 million in revenue and about $610,000 in management-adjusted EBITDA, indicating solid performance in the aerospace manufacturing sector.
- Operational Continuity: A&B Aerospace will continue to operate from its existing facility in Azusa, California, under a lease signed at closing, ensuring business continuity and stability.
See More
PMGC Acquires A&B Aerospace to Enhance Precision Manufacturing Platform
- Transaction Overview: PMGC Holdings Inc. has acquired 100% of A&B Aerospace for $4.5 million in cash, marking the fifth acquisition in the past twelve months and advancing PMGC's strategy to consolidate U.S. precision manufacturing companies.
- Financial Performance: For the twelve months ending February 2026, A&B Aerospace reported approximately $5 million in revenue and about $610,000 in management-adjusted EBITDA, indicating robust profitability and demand in the aerospace sector.
- Growing Market Demand: With the U.S. defense budget reaching $839 billion, PMGC anticipates sustained demand for certified U.S.-based precision manufacturers, particularly in aerospace and defense, driving future business expansion.
- Strategic Fit: A&B Aerospace, with 76 years of operational history and AS9100D and ISO 9001:2015 certifications, aligns with PMGC's acquisition criteria, enhancing its market position in high-barrier and mission-critical applications.
See More
NorthStrive Files New Patent for Muscle Loss Treatment
- Patent Application Expansion: NorthStrive Biosciences has filed a new U.S. patent application (Application No. 19/655,160) aimed at expanding its proprietary EL-22 technology into human pharmaceutical applications, particularly for patients suffering from muscle loss, showcasing the company's innovative potential in the biopharmaceutical sector.
- Clear Therapeutic Targets: The patent covers specific dosing regimens and formulations targeting muscle-wasting conditions such as sarcopenia and certain neurological disorders, indicating the company's commitment to addressing a wide range of muscle health issues with significant market demand.
- Strengthened IP Strategy: This filing not only enhances NorthStrive's intellectual property portfolio but also reflects the company's ongoing focus on muscle health therapeutics, potentially providing strong support for future market competition.
- Broad Market Prospects: As NorthStrive's lead asset, EL-22 leverages a myostatin-engineered probiotic approach, expected to offer new solutions for patients undergoing weight loss treatments, further expanding its influence in the biopharmaceutical and adjacent markets.
See More
GB Capital Advises PMGC on A&B Aerospace Acquisition
- Acquisition Overview: PMGC Holdings Inc. has completed the acquisition of A&B Aerospace, marking its fifth acquisition in the past 12 months and further advancing its consolidation strategy in the U.S. precision manufacturing sector, which is expected to enhance its market competitiveness.
- Stable Customer Base: A&B Aerospace has established contracts with long-standing Tier 1 customers such as Boeing, Honeywell, and Moog, ensuring ongoing demand in the aerospace and defense sectors, thereby providing PMGC with a stable revenue stream.
- Significant Technical Advantages: A&B Aerospace specializes in high-tolerance machining and complex component manufacturing, operating over 20 modern CNC machines with full 5-axis capabilities, maintaining strict tolerances of ±0.0001 inches, which enhances PMGC's technical barriers to entry.
- Comprehensive Financial Support: GB Capital provided extensive financial due diligence and post-closing integration support throughout the transaction lifecycle, including standardizing financial reporting and internal controls, ensuring PMGC's compliance and operational efficiency post-acquisition.
See More
Elevai Labs Reports Significant Q1 Revenue Growth
- Revenue Growth: Elevai Labs reported Q1 revenue of $0.68 million, indicating strong market performance that is expected to drive future business expansion and investment opportunities.
- Asset Increase: As of March 31, 2026, total assets rose to approximately $26.0 million, up 102% from $12.87 million at year-end 2025, demonstrating the company's success in capital management and resource allocation.
- Shareholder Equity Growth: Shareholders' equity increased to approximately $12.6 million, a 61% rise from $7.84 million at year-end 2025, reflecting enhanced profitability and increased shareholder value.
- Improved Cash Flow: Cash and cash equivalents ended the quarter at approximately $14.4 million, significantly up from $5.4 million at year-end 2025, marking the largest cash balance in the company's history and providing ample funding for future investments.
See More
PMGC Holdings Reports Q1 2026 Financial Results with Significant Growth
- Significant Asset Growth: As of March 31, 2026, PMGC Holdings reported total assets of approximately $26 million, a 102% increase from $12.87 million at the end of 2025, reflecting strong performance in financing and M&A activities that enhance financial stability.
- Shareholder Equity Increase: Shareholder equity rose to approximately $12.6 million, up 61% from $7.84 million at year-end 2025, indicating improved profitability and providing a stronger capital base for future investments and expansions.
- Revenue Surge: Q1 2026 revenue reached approximately $682,000, a significant increase from zero in the same period of 2025, and surpassing the entire FY2025 revenue of $590,000, demonstrating rapid revenue growth post-acquisition.
- Strategic Investment Expansion: The company formed NorthStrive Defense Tech LLC in April 2026 to focus on acquiring and commercializing advanced defense technologies, while also entering into a $40 million equity purchase agreement with an investor, ensuring future capital flexibility to support M&A activities.
See More
PMGC Holdings Acquires A&B Aerospace for $4.5M
- Acquisition Overview: PMGC Holdings has acquired A&B Aerospace for $4.5 million in cash, with $4.275 million paid at closing and a $225,000 indemnification holdback, demonstrating the company's commitment to expanding in the aerospace manufacturing sector.
- Strategic Acquisition Progress: This deal marks PMGC's fifth acquisition in the past twelve months, further advancing its roll-up strategy focused on assembling a U.S. precision manufacturing platform of AS9100D-certified CNC machining businesses serving aerospace, defense, and industrial markets.
- Financial Performance Highlights: For the trailing twelve-month period ending February 28, 2026, A&B Aerospace recorded approximately $5 million in revenue and about $610,000 in management-adjusted EBITDA, indicating solid performance in the aerospace manufacturing sector.
- Operational Continuity: A&B Aerospace will continue to operate from its existing facility in Azusa, California, under a lease signed at closing, ensuring business continuity and stability.
See More
PMGC Acquires A&B Aerospace to Enhance Precision Manufacturing Platform
- Transaction Overview: PMGC Holdings Inc. has acquired 100% of A&B Aerospace for $4.5 million in cash, marking the fifth acquisition in the past twelve months and advancing PMGC's strategy to consolidate U.S. precision manufacturing companies.
- Financial Performance: For the twelve months ending February 2026, A&B Aerospace reported approximately $5 million in revenue and about $610,000 in management-adjusted EBITDA, indicating robust profitability and demand in the aerospace sector.
- Growing Market Demand: With the U.S. defense budget reaching $839 billion, PMGC anticipates sustained demand for certified U.S.-based precision manufacturers, particularly in aerospace and defense, driving future business expansion.
- Strategic Fit: A&B Aerospace, with 76 years of operational history and AS9100D and ISO 9001:2015 certifications, aligns with PMGC's acquisition criteria, enhancing its market position in high-barrier and mission-critical applications.
See More
NorthStrive Files New Patent for Muscle Loss Treatment
- Patent Application Expansion: NorthStrive Biosciences has filed a new U.S. patent application (Application No. 19/655,160) aimed at expanding its proprietary EL-22 technology into human pharmaceutical applications, particularly for patients suffering from muscle loss, showcasing the company's innovative potential in the biopharmaceutical sector.
- Clear Therapeutic Targets: The patent covers specific dosing regimens and formulations targeting muscle-wasting conditions such as sarcopenia and certain neurological disorders, indicating the company's commitment to addressing a wide range of muscle health issues with significant market demand.
- Strengthened IP Strategy: This filing not only enhances NorthStrive's intellectual property portfolio but also reflects the company's ongoing focus on muscle health therapeutics, potentially providing strong support for future market competition.
- Broad Market Prospects: As NorthStrive's lead asset, EL-22 leverages a myostatin-engineered probiotic approach, expected to offer new solutions for patients undergoing weight loss treatments, further expanding its influence in the biopharmaceutical and adjacent markets.
See More
